TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8424504

Group type: EXPERIMENTAL
Intervention: 0.5 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine + 75 mg IM diclofenac
Number of subjects: 120

Group type: COMPARATOR
Intervention: 4 mg epidural morphine + 3 mL normal saline IM
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall pain relief
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Incidence of nausea or vomiting, pruritus, and bleeding
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Severity of pruritus
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bradyspnea
Number of subjects: 120
Study: 3566307

Group type: EXPERIMENTAL
Intervention: Cisplatin (10-20 mg/m2 i.v., on days 1-5 or 50-100 mg/m2 i.v., on day 1, every 3 to 4 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 69
Study: 29281036

Group type: EXPERIMENTAL
Intervention: Iclaprim 80 mg intravenously every 12 hours for 5-14 days
Number of subjects: 600

Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg intravenously every 12 hours for 5-14 days
Number of subjects: 600
Study: 27428533

Group type: EXPERIMENTAL
Intervention: Self-massage at the musculotendinous junction for 3 min daily, five times per week, for 12 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study: 24515493

Group type: EXPERIMENTAL
Intervention: Facilitated physician small-group curriculum (19 biweekly discussion groups for 9 months) with 1 hour of paid time every other week.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control arm (no intervention).
Number of subjects: 74

Group type: COMPARATOR
Intervention: Nontrial cohort (350 participants).
Number of subjects: 74
Study: 22351480

Group type: EXPERIMENTAL
Intervention: 50 mg MG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 mg MG (thrice a day for 1 week)
Number of subjects: 20
Study: 20215047

Group type: EXPERIMENTAL
Intervention: Multiple tailoring and counselling (MTC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Multiple tailoring (MT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 15
Study: 18374423

Group type: EXPERIMENTAL
Intervention: Metformin plus sibutramine (10‐20 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16227668

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crude version of EBM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial sponsors of clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bureaucrats employing EBM practices
Number of subjects: 0
Study: 11777716

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine ophthalmic solution 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Loteprednol etabonate ophthalmic suspension 0.5%
Number of subjects: 60
Study: 9651632

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine 2
Number of subjects: 0
Study: 8016555

Group type: EXPERIMENTAL
Intervention: 2.2 mM CHX mouthrinses used twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 11.9 mM NaF rinses used daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of CHX and NaF rinses
Number of subjects: 9

Group type: COMPARATOR
Intervention: F- rinses alone
Number of subjects: 9
Study: 2573964

Group type: COMPARATOR
Intervention: Prazosin (Minipress)
Number of subjects: 344
Study: 30253197

Group type: EXPERIMENTAL
Intervention: 10 mg vortioxetine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 20 mg vortioxetine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 15 mg escitalopram
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 27344218

Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation target range (85%-89%)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Higher oxygen saturation target range (91%-95%)
Number of subjects: 810
Study: 24724089

Group type: EXPERIMENTAL
Intervention: Treadmill interval training (4 × 4 minutes at 90‐95% of maximal heart rate, 3 days a week for 8 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional rehabilitation control group
Number of subjects: 24
Study: 23199977

Group type: EXPERIMENTAL
Intervention: Inhaled procaterol before exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no inhaled procaterol)
Number of subjects: 21
Study: 20391086

Group type: EXPERIMENTAL
Intervention: Walking training (7-week, four sessions a week)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (continued daily life)
Number of subjects: 27
Study: 18795931

Group type: EXPERIMENTAL
Intervention: Repeated Open Application Test (ROAT) with MDBGN
Number of subjects: 18

Group type: COMPARATOR
Intervention: Patch Test with MDBGN
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Accumulated ROAT doses (1, 2, and 3 weeks) with MDBGN
Number of subjects: 18
Study: 15949196

Group type: EXPERIMENTAL
Intervention: Clinically stable malarial anaemia
Number of subjects: 255
Study: 12053589

Group type: EXPERIMENTAL
Intervention: Neuron specific enolase (NSE) evaluation
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 146
Study: 10689258

Group type: EXPERIMENTAL
Intervention: AVGCS
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (uncovered stents)
Number of subjects: 170
Study: 9015593

Group type: EXPERIMENTAL
Intervention: Jogging protocol (10 min at 60% of maximum age predicted heart rate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stretching protocol (five 30 s static stretches with 30 s rest between stretches)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined protocol (jogging followed by stretching)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stretching only protocol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Running only protocol
Number of subjects: 24
Study: 1414430

Group type: EXPERIMENTAL
Intervention: Brief counseling session from family physician
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Brief counseling session from family physician + free supply of nicotine gum
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Brief health-education session from primary care nurse
Number of subjects: 425
Study: 4076354

Group type: EXPERIMENTAL
Intervention: Daily structured physical exercise for 10 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Twice daily inspiratory muscle training by resistive breathing for 10 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Daily placebo training for 10 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 21
Study: 31656094

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Average-protein diet
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Bottom tertile of SBP/DBP-PGS
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Gene-diet interaction
Number of subjects: 692
Study: 29428926

Group type: EXPERIMENTAL
Intervention: Articulatory costal manual therapy (AC group)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Neurolymphatic therapy (NL group)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Articulatory spinal manual therapy (AS group)
Number of subjects: 112
Study: 26782620

Group type: EXPERIMENTAL
Intervention: e‐IMR intervention (e-health application combined with face-to-face delivery of the Illness Management & Recovery programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Illness Management & Recovery programme (control condition)
Number of subjects: 0
Study: 24026982

Group type: EXPERIMENTAL
Intervention: 1-h RFES session from the CAN-FIT programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study: 22137666

Group type: EXPERIMENTAL
Intervention: Once‐per‐week EPO, 1200 U/kg/dose, subcutaneously for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3‐times‐a‐week EPO, 400 U/kg/dose, subcutaneously for 4 weeks
Number of subjects: 20
Study: 20730261

Group type: EXPERIMENTAL
Intervention: Therapeutic TENS (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo TENS (n = 12)
Number of subjects: 25
Study: 17688113

Group type: EXPERIMENTAL
Intervention: Positive mood as a mediator
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Proposed model
Number of subjects: 247
Study: 15650312

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily (bid)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 11291084

Group type: EXPERIMENTAL
Intervention: Intradermal injection of synthetic mutant ras peptides with granulocyte-macrophage colony-stimulating factor as adjuvant
Number of subjects: 48
Study: 9384020

Group type: EXPERIMENTAL
Intervention: Aerosolized oxygen with antibacterial, antiphlogistic drugs, expectorants, antispastic and antiasthmatic drugs
Number of subjects: 148

Group type: COMPARATOR
Intervention: Convenient simple aerosolized oxygen inhalation
Number of subjects: 148
Study: 8202964

Group type: EXPERIMENTAL
Intervention: Citalopram (10 to 40 mg/d) for 3 and 6 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 3109894

Group type: EXPERIMENTAL
Intervention: Ultipor Pall BB50 filter included 'in series' in the Bain circuit
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no filter)
Number of subjects: 81
Study: 2239815

Group type: EXPERIMENTAL
Intervention: Yomeishu (YMS) 20 ml twice a day before meals for 12 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Yomeishu (YMS)
Number of subjects: 50
Study: 1093464

Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide therapy (DAT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 13
Study: 31813354

Group type: EXPERIMENTAL
Intervention: Enhanced and prolonged Holter‐ECG monitoring (EPM) (3× 10‐day Holter‐ECG)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Usual stroke care diagnostic work‐up (Control)
Number of subjects: 398
Study: 31775721

Group type: EXPERIMENTAL
Intervention: Indirect composite overlay restoration in normal bone level (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Direct composite fillings in normal bone level (Group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indirect composite overlay restoration in furcation involvement (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct composite fillings in furcation involvement (Group 4)
Number of subjects: 60
Study: 27805571

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 800 mg once a day for 6 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir 400 mg twice daily for 6 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 26114120

Group type: EXPERIMENTAL
Intervention: Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week intensive program for diabetes weight management
Number of subjects: 120
Study: 23102873

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injected into facial muscles within 72 hours postoperatively.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no BTA injection).
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups assessed using PSAS, OSAS, and VSS scores.
Number of subjects: 30
Study: 21647903

Group type: EXPERIMENTAL
Intervention: Nasal tip projection (NTP) ratios (Goode, Simons, Baum, Powell, Crumley)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Baum, Powell, and Simons ratios
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Goode and Crumley ratios
Number of subjects: 300
Study: 19365652

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels pre-IVIG
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: BNP levels pre-IVIG
Number of subjects: 43
Study: 16704952

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with 5% energy from fructose (low fruit diet)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with 15% energy from fructose (high fruit diet)
Number of subjects: 15
Study: 15081455

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg)
Number of subjects: 344
Study: 11240959

Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT) combined with specific IgE measurement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combination of positive APT results and specific IgE measurement
Number of subjects: 98
Study: 9264422

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator placement
Number of subjects: 542

Group type: COMPARATOR
Intervention: Best medical therapy (antiarrhythmic drug therapy)
Number of subjects: 542
Study: 7899862

Group type: COMPARATOR
Intervention: LAC group
Number of subjects: 58

Group type: COMPARATOR
Intervention: ET group
Number of subjects: 58
Study: 3582605

Group type: EXPERIMENTAL
Intervention: MOCCA (methylprednisolone, vincristine, CCNU, cyclophosphamide, melphalan)
Number of subjects: 130

Group type: COMPARATOR
Intervention: MP (intermittent melphalan and prednisone)
Number of subjects: 130
Study: 31332957

Group type: EXPERIMENTAL
Intervention: Intervention group 1 (10-week online physical activity program)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Intervention group 2 (same program plus activity tracker)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 351
Study: 29135066

Group type: EXPERIMENTAL
Intervention: Electrocardiographic monitoring with the AliveCor™ device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual cardiac care
Number of subjects: 0
Study: 28049642

Group type: EXPERIMENTAL
Intervention: Clofarabine (10 mg/m2 on days 1-5 of each of both cycles)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control (idarubicine-cytarabine and amsacrine-cytarabine without clofarabine)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Clofarabine (in subgroup analyses)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Clofarabine
Number of subjects: 393
Study: 25982338

Group type: EXPERIMENTAL
Intervention: Propranolol combined with oral prednisolone for the initial 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propranolol alone for 6 months
Number of subjects: 40
Study: 23063625

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine plus hyaluronic acid 20mg and capsular distension
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% lidocaine plus triamcinolone 40mg IA injection
Number of subjects: 100
Study: 21750266

Group type: EXPERIMENTAL
Intervention: ALA (1,800 mg/day) for 2 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lipid infusion with ALA pretreatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lipid infusion without ALA pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 8
Study: 19401659

Group type: EXPERIMENTAL
Intervention: Propofol (0.2 mg kg(‐1) bolus, followed by infusion at 2 mg kg(‐1) h(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC, infusion at 5 mg kg(‐1) h(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 60
Study: 16782569

Group type: EXPERIMENTAL
Intervention: 2-portal endoscopic release (2-PER)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open release (OR) with two minimised incisions
Number of subjects: 10
Study: 15290395

Group type: EXPERIMENTAL
Intervention: Perioperative PGE1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard postoperative treatment (Control)
Number of subjects: 40
Study: 11894980

Group type: EXPERIMENTAL
Intervention: Oral combined continuous hormone replacement therapy (HRT) with Kliogest (oestradiol 2 mg, norethisterone 1 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 9469797

Group type: EXPERIMENTAL
Intervention: 4 mg perindopril administered at 0900 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 mg perindopril administered at 2100 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8194494

Group type: EXPERIMENTAL
Intervention: Rapeseed oil-enriched diet
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sunflower oil-enriched diet
Number of subjects: 101
Study: 3074777

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg twice a day
Number of subjects: 80
Study: 31874212

Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC); mean cord clamping time 5:49 ± 2:37 min; infants needed less time to reach respiratory stability (5:54 ± 2:27 min).
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard delayed cord clamping (DCC); mean cord clamping time 1:02 ± 0:30 min; infants needed more time to reach respiratory stability (7:07 ± 2:54 min).
Number of subjects: 37
Study: 29895225

Group type: EXPERIMENTAL
Intervention: Service screening mammography for women aged 50-64 and 45-69
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Service screening mammography for women aged 50-64
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Service screening mammography for women aged 45-49 and 65-74
Number of subjects: 0
Study: 28545321

Group type: EXPERIMENTAL
Intervention: Intranasal MLV vaccine (containing BoHV-1, BRSV, BPIV-3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous MLV vaccine (containing BVDV-1, BVDV-2, BoHV-1, BRSV, BPIV-3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intranasal MLV vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 24646115

Group type: EXPERIMENTAL
Intervention: PDL-S
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CCLAD
Number of subjects: 41

Group type: COMPARATOR
Intervention: IANB
Number of subjects: 41
Study: 23062631

Group type: EXPERIMENTAL
Intervention: Topical 5% permethrin cream and a comprehensive scabies control programme including hygiene monitoring and health education classes.
Number of subjects: 4824

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 4824

Group type: EXPERIMENTAL
Intervention: Intervention programme including hygiene practices and health education.
Number of subjects: 4824

Group type: EXPERIMENTAL
Intervention: Intervention programme including scabies knowledge education.
Number of subjects: 4824
Study: 21906391

Group type: EXPERIMENTAL
Intervention: azelnidipine (16 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: amlodipine (5 mg/day)
Number of subjects: 17
Study: 19231250

Group type: EXPERIMENTAL
Intervention: Endoluminal PTFE thrupass (WL Gore & Ass)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgical polytetrafluoroethylene (PTFE) bypass to proximal popliteal artery
Number of subjects: 120
Study: 16838613

Group type: EXPERIMENTAL
Intervention: Flunarizina
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cinarizina
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12771112

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 4532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4532
Study: 10841241

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 61
Study: 9241336

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg‐1, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline, n = 25)
Number of subjects: 50
Study: 1570380

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study: 3883767

Group type: EXPERIMENTAL
Intervention: Nifedipine in cardioplegic solution (average dose 407 +/- 22 micrograms at one center; 476 +/- 22 micrograms at another center)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (no nifedipine)
Number of subjects: 205
Study: 30312980

Group type: EXPERIMENTAL
Intervention: Peyton's four-step approach
Number of subjects: 491

Group type: COMPARATOR
Intervention: Traditional peer teaching
Number of subjects: 491
Study: 29149381

Group type: EXPERIMENTAL
Intervention: Patient education programme (DTTP) for conventional insulin therapy in outpatient group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Patient education programme (DTTP) for conventional insulin therapy in inpatient group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Outpatient group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Inpatient group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 25961725

Group type: EXPERIMENTAL
Intervention: Social influence manipulation during effort allocation trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effort allocation under low probability of reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effort allocation under high probability of reward
Number of subjects: 0
Study: 24624850

Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration with Ropivacaine
Number of subjects: 60
Study: 21427150

Group type: EXPERIMENTAL
Intervention: Intermittent cervical traction
Number of subjects: 79

Group type: COMPARATOR
Intervention: Infrared irradiation alone (Control)
Number of subjects: 79
Study: 19037084

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg QD
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg QD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Indomethacin 75 mg BID
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lisinopril 40 mg QD
Number of subjects: 16
Study: 17959549

Group type: EXPERIMENTAL
Intervention: Bronchovaxom treatment (3.5 mg daily for 10 days every month for 3 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Budesonide aerosol (200 microg once or twice daily for 3 months)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy control group (10 healthy infants)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Basic treatment group (budesonide)
Number of subjects: 43